Showing 1 - 10 of 15
Persistent link: https://www.econbiz.de/10011294610
Persistent link: https://www.econbiz.de/10010485559
Persistent link: https://www.econbiz.de/10003193758
Persistent link: https://www.econbiz.de/10003718171
Persistent link: https://www.econbiz.de/10011409439
Persistent link: https://www.econbiz.de/10011713223
Persistent link: https://www.econbiz.de/10011713225
This paper investigates the impact of depression on labor force participation among older workers. Empirically, we use two analytic strategies and rely on a sample drawn from the Health and Retirement Survey. Depression directly and indirectly increases individuals%u2019 probability of retiring...
Persistent link: https://www.econbiz.de/10012780122
Since the 1984 passage of the Waxman-Hatch Act, generic prescription drugs have become central to disease treatment and generic drug entry and price competition has been vigorous in the U.S. Nonetheless, recent policy concern has focused on potential supply inadequacy and price increases among...
Persistent link: https://www.econbiz.de/10012950823
Drugs like bevacizumab ($50,000 per treatment episode) and ipilimumab ($120,000 per episode) have fueled the perception that the launch prices of anticancer drugs are increasing over time. Using an original dataset of 58 anticancer drugs approved between 1995 and 2013, we find that launch...
Persistent link: https://www.econbiz.de/10013030058